{"groups":[{"description":"Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)","id":"FG000","title":"ALK-positive NSCLC With Progression"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"62"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"62"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participants were referred by means of their treating physician or social media to a study website (https://alcmi.net/research/spacewalk-study/) and completed a contact form indicating their interest in participating in the study and answered a prescreening questionnaire. If the patients indicated they have ALK-positive NSCLC and are progressing on an ALK TKI, they were contacted by the study staff who then released access to an online consent form to the patient."}